What's Happening?
The Rosen Law Firm has announced a securities fraud lawsuit against Soleno Therapeutics, Inc. The lawsuit pertains to allegations that the company made false or misleading statements regarding its Phase 3 clinical trial program for diazoxide choline extended-release
tablets (DCCR). The firm claims that Soleno downplayed safety concerns related to DCCR, which is used to treat hyperphagia in individuals with Prader-Willi syndrome. Investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025, are encouraged to join the class action. The deadline for lead plaintiff applications is May 5, 2026.
Why It's Important?
This lawsuit is significant as it highlights potential risks and liabilities for Soleno Therapeutics, which could impact its financial standing and investor confidence. The allegations of misleading safety information could lead to regulatory scrutiny and affect the commercial viability of DCCR. Investors who suffered losses due to the alleged misrepresentations may seek compensation, which could result in substantial financial settlements. The outcome of this case could also influence the practices of other pharmaceutical companies in terms of transparency and disclosure.
What's Next?
Investors interested in participating in the lawsuit must apply to be lead plaintiffs by May 5, 2026. The case will proceed through the legal system, potentially leading to a trial or settlement. The outcome could affect Soleno's stock price and its ability to market DCCR. Regulatory bodies may also take interest in the case, which could lead to further investigations or actions against the company.
